US FDA allows Rotarix vaccinations to resume
This article was originally published in Scrip
Executive Summary
The US FDA is recommending that practitioners resume inoculations with GlaxoSmithKline's Rotarix following an almost two-month pause in the rotavirus vaccine's use owing to the presence of porcine circovirus-1 (PCV-1) contamination.